<DOC>
	<DOCNO>NCT00725075</DOCNO>
	<brief_summary>The purpose study determine whether MK-8435 ( Org 25935 ) effective placebo improve negative symptom participant schizophrenia concurrently treat stable dose second generation antipsychotic .</brief_summary>
	<brief_title>Adjuvant Treatment With Glycine Uptake Inhibitor Participants With Negative Symptoms Schizophrenia ( P05695 ) ( MK-8435-001 )</brief_title>
	<detailed_description>The primary feature schizophrenia characterize positive ( irrational thought and/or behavior ) negative symptom . Negative symptom gross absence normal behavior emotion , usually include general lack engagement , social withdrawal , loss goal-directed behavior . Negative symptom may strongly affect daytime activity quality life . The effect currently available antipsychotic negative symptom satisfactory leave much room improvement . MK-8435 ( Org 25935 ) investigational drug may help correct characteristic schizophrenia facilitate messenger function amino acid brain , call glutamate . Preliminary data suggest lower glutamate level schizophrenia associate failure activate relevant area forebrain prominent negative symptom .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Is diagnose nonfirst episode schizophrenia meeting Diagnostic Statistical Manual ( Version IV ) criterion Is receive stable treatment one follow SGA : aripiprazole , olanzapine , quetiapine , risperidone , ziprasidone Is nonacute phase illness clinically stable 3 month prior study start demonstrate : treatment current SGA least 12 week prior study start ; increase level psychiatric care due worsen symptom least 12 week prior study start ; dose change SGA change medication treat symptom schizophrenia 4 week prior study start Has score ≥4 3 follow Positive Negative Symptoms Scale ( PANSS ) negative subscale item study start : blunt affect , emotional withdrawal , poor rapport , passive social withdrawal , lack spontaneity , motor retardation , active social avoidance Has overall PANSS negative subscale score &gt; 20 Has overall PANSS positive subscale score ≥20 Has score ≥5 2 follow PANSS positive subscale item study start : delusion , hallucinatory behavior , excitement , grandiosity , suspiciousness/persecution Has score ≥9 modify InterSePT Scale Suicidal Thinking Has score ≥9 Calgary Depression Scale Schizophrenia Has score ≥3 clinical global impression Parkinsonism abbreviate Extrapyramidal Symptom Rating Scale Has untreated uncompensated clinically significant renal , endocrine , hepatic , respiratory , cardiovascular , hematological , immunological cerebrovascular disease , malignancy , chronic and/or degenerative process Has history seizure disorder beyond childhood take anticonvulsant prevent seizures Has diagnosis mental retardation organic brain syndrome Has clinically relevant visual disturbance , cataract , color blindness , macular degeneration , glaucoma , retinal disease Has concurrent diagnosis substance dependence nicotine caffeine dependence past 6 month prior study start Has positive result urine alcohol/drug screen alcohol illicit drug Is pregnant breastfeeding Is treat high dos benzodiazepine ( &gt; 4 mg per day lorazepam equivalent ) Has imminent risk selfharm harm others Has treat clozapine past 6 month prior study start Has treat lithium , valproate , lamotrigine , pregabalin , gabapentin , carbamazepine past 12 week prior study start Has start treatment dose change ( additional ) antipsychotic , antidepressant , hypnotic anxiolytic past 4 week prior study start Has demonstrate benefit antipsychotic treatment within previous five year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Negative symptom</keyword>
	<keyword>Glycine Uptake inhibitor</keyword>
	<keyword>Add-on treatment</keyword>
	<keyword>Second Generation Antipsychotic</keyword>
</DOC>